Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Common Equity (2016 - 2025)

vTv Therapeutics' Common Equity history spans 12 years, with the latest figure at $64.4 million for Q4 2025.

  • For Q4 2025, Common Equity rose 350.58% year-over-year to $64.4 million; the TTM value through Dec 2025 reached $64.4 million, up 350.58%, while the annual FY2025 figure was $64.4 million, 350.58% up from the prior year.
  • Common Equity for Q4 2025 was $64.4 million at vTv Therapeutics, down from $70.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $70.5 million in Q3 2025 and bottomed at -$56.3 million in Q1 2021.
  • The 5-year median for Common Equity is -$9.1 million (2021), against an average of -$2.4 million.
  • The largest annual shift saw Common Equity plummeted 196.54% in 2023 before it soared 350.58% in 2025.
  • A 5-year view of Common Equity shows it stood at -$9.7 million in 2021, then dropped by 10.27% to -$10.7 million in 2022, then tumbled by 129.8% to -$24.7 million in 2023, then skyrocketed by 157.95% to $14.3 million in 2024, then skyrocketed by 350.58% to $64.4 million in 2025.
  • Per Business Quant, the three most recent readings for VTVT's Common Equity are $64.4 million (Q4 2025), $70.5 million (Q3 2025), and $2.4 million (Q2 2025).